Celltrion to expand new drug-substance production in Songdo, investing 1.2 trillion won
Celltrion said March 24 it will secure additional manufacturing capacity, including a major expansion at its headquarters campus in Songdo, Incheon, with investment exceeding 1 trillion won.
The company said the plan is intended to meet rising global demand for biopharmaceuticals and strengthen manufacturing competitiveness. The investment will be carried out in phases from this year through 2030 and includes infrastructure expansion across the Songdo campus, a U.S. production base and domestic sites.
At Songdo, Celltrion will invest 1.2265 trillion won to expand Plants 4 and 5 simultaneously, bringing total capacity to 180,000 liters.
The new facilities will apply automation and smart-factory technology, the company said, enabling production ranging from small-batch, multi-product runs to large-scale manufacturing. It said the system is expected to support faster production of future biosimilars and new drugs.
Celltrion also finalized the scale of an expansion at its Branchburg, New Jersey, facility to strengthen competitiveness in the U.S. market.
It plans to increase capacity there from 66,000 liters to 75,000 liters, securing total drug-substance production capacity of 141,000 liters. The Branchburg site is expected to play a key role in local supply for the Celltrion Group and in expanding its contract manufacturing (CMO) business, the company said.
Celltrion is also moving to strengthen drug-product production. A new drug-product facility being expanded at Songdo is nearing completion within the year and, once operational, will be able to produce 6.5 million liquid vials annually. Combined with the maximum output of the Plant 2 drug-product line, Songdo would have total capacity of 10.5 million vials, the company said.
A new drug-product plant planned for an industrial complex in Yesan, South Chungcheong province, has secured its site and is scheduled to begin design work within the year. Celltrion said that once the Yesan plant is completed and Celltrion Pharm’s planned expansion of prefilled syringe (PFS) production is finished, the group would be able to internalize about 90% of its global drug-product needs. The company said it expects significant manufacturing cost savings compared with overseas drug-product CMO production.
HLB Life Science wins tissue bank license, expanding human tissue graft business
HLB Life Science said March 24 it has obtained a tissue bank license and will move ahead with expanding its human tissue graft business. The approval provides a foundation to handle human tissues including bone, cartilage, fascia and skin, the company said.
The product HLB Life Science will distribute, “Freedom Inject Refill,” is an injectable acellular dermal allograft derived from human tissue. Using acellular dermis as its raw material, it is used to treat damaged tissue such as ligaments, tendons and muscles and to support surgical procedures, the company said.
The company said the material is produced by removing cells and fat components from skin-derived tissue while preserving extracellular matrix components needed for tissue regeneration, including collagen. It is expected to be used broadly for reconstruction, regeneration and recovery of damaged soft tissue and joints.
Initial supply targets include orthopedic surgery, neurosurgery, obstetrics and gynecology, and urology clinics nationwide, with distribution to be expanded gradually, the company said.
Aribio says ADPD 2026 presentation supports reliability of global Phase 3 data for AR1001
Aribio said March 24 that Sharon Sha, a Stanford University professor and the global principal investigator, presented an update on the global Phase 3 program for its oral Alzheimer’s disease treatment candidate AR1001 at ADPD 2026 in Copenhagen.
POLARIS-AD is a large global Phase 3 trial evaluating the efficacy and safety of AR1001 (30 mg, once daily) in patients with early Alzheimer’s disease. A total of 1,535 patients are enrolled across 13 countries in North America, Europe and Asia, making it the largest trial among oral treatments currently in development, the company said.
In the presentation, Sha said, “The baseline demographic characteristics and cognitive and functional indicators in POLARIS-AD are similar to those in existing global registration trials, and no unexpected safety signals have been observed to date.”
Sha also highlighted what Aribio described as AR1001’s mechanistic differentiation. “AR1001 has very high blood-brain barrier (BBB) permeability, and its selectivity for PDE5 is superior to PDE6 and PDE11, resulting in fewer side effects than drugs in the same class,” she said. Aribio said this could be a competitive advantage in a market where long-term use is required.
Aribio said it plans to release top-line data from the global Phase 3 trial in the third quarter and is aiming to submit a new drug application to the U.S. Food and Drug Administration in the second half of the year.
Hugel’s Wellage runs mobile pop-up events to deepen consumer engagement
Hugel said March 24 that its clinical cosmetics brand Wellage expanded offline consumer outreach through hands-on events.
In collaboration with Beauty+, Wellage held a three-day “moving pop-up” from March 19 to 21 at university campuses and around Seongsu-dong. The company said the event was designed to strengthen brand experience among its core targets, including college students and the MZ generation, and drew about 2,800 visitors over three days.
Wellage ran trial programs for its flagship “Real Hyaluronic Blue 100 Ampoule” and its new “Real Hyaluronic Soothing Cream,” and held a participatory product-draw event to gather consumer feedback, the company said.
Daewoong Pharmaceutical signs supply deal with TR for digital spirometry device “The Spiro Kit”
Daewoong Pharmaceutical said March 24 it signed a supply agreement with TR for a digital spirometry device, “The Spiro Kit,” and will strengthen sales to clinics, hospitals and health screening centers nationwide.
Under the agreement, TR will handle development and manufacturing, while Daewoong Pharmaceutical will oversee distribution, sales and marketing through its nationwide network, the company said.
Daewoong described the deal as a strategic partnership combining a medical device developer’s technology with a pharmaceutical company’s sales infrastructure. TR is expected to secure stable sales channels and marketing capabilities, while Daewoong Pharmaceutical adds a digital medical device to its business portfolio, it said.
The companies said the partnership is aimed at meeting rising demand for pulmonary function tests as South Korea’s national health screening system is revised. With pulmonary function testing (PFT) formally added to general health screenings starting this year, people ages 56 and 66 will have an opportunity to detect major respiratory diseases such as chronic obstructive pulmonary disease (COPD) earlier through screenings, the company said.
* This article has been translated by AI.
Copyright ⓒ Aju Press All rights reserved.